Advertisement
Advertisement

Indicator

Free Access

Pay per View

Partial Free Access

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Theme Issue
Platelets: basic mechanisms and translational implications

DOI: http://dx.doi.org/10.1160/TH13-03-0213
Issue: 2013: 110/5 (Nov) pp. 857-1085
Pages: 931-939

Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin

H. J. Metzner (1), S. W. Pipe (2), T. Weimer (1), S. Schulte (1)

(1) CSL Behring GmbH, Marburg, Germany; (2) Departments of Pediatrics and Pathology, University of Michigan Medical Center, Ann Arbor, Michigan, USA

Summary

The prophylactic treatment of haemophilia B and the management of haemophilia A or B with inhibitors demand frequent administrations of coagulation factors due to the suboptimal half-lives of the products commercially available and currently in use, e.g. recombinant factor IX (rFIX) and recombinant factor VIIa (rFVIIa), respectively. The extension of the half-lives of rFIX and rFVIIa could allow for longer intervals between infusions and could thereby improve adherence and clinical outcomes and may improve quality of life. Albumin fusion is one of a number of different techniques currently being examined to prolong the half-life of rFIX and rFVIIa. Results from a phase I clinical trial demonstrated that the recombinant fusion protein linking FIX to albumin (rIX-FP) has a five-times longer half-life than rFIX, and preclinical studies with the recombinant fusion protein linking FVIIa to albumin (rVIIa-FP) suggest that rVIIa-FP possesses a significantly extended half-life versus rFVIIa. In this review, we describe albumin fusion technology and examine the recent progress in the development of rIX-FP and rVIIa-FP.

Keywords

albumin fusion, Coagulation factor IX, coagulation factor VIIa, half-life extension

DOI

http://dx.doi.org/10.1160/TH13-03-0213

You may also be interested in...

1.

Thomas Weimer, Wilfried Wormsbächer, Ulrich Kronthaler, Wiegand Lang, Uwe Liebing, Stefan Schulte

Thromb Haemost 2008 99 4: 659-667

http://dx.doi.org/10.1160/TH07-08-0525

2.

Hubert J. Metzner; Thomas Weimer; Ulrich Kronthaler; Wiegand Lang; Stefan Schulte

Thromb Haemost 2009 102 4: 634-644

http://dx.doi.org/10.1160/TH09-04-0255